The 1 analysts offering 12-month price forecasts for ReShape Lifesciences Inc have a median target of 10.25, with a high estimate of 10.25 and a low estimate of 10.25. The median estimate represents a +260.92% increase from the last price of 2.84.
The current consensus among 1 polled investment analysts is to Buy stock in ReShape Lifesciences Inc. This rating has held steady since June, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.12
Reporting Date Nov 05
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.